DNA Studija - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 40,425 | 43,185 | 76,288 | 116,787 | 168,109 | 134,150 | 169,035 | 200,652 |
| Profit before tax | 1,482 | 6,262 | 1,960 | 4,597 | -3,293 | -1,176 | 662 | 2,424 |
| Net profit | 1,482 | 5,933 | 1,861 | 4,346 | -3,612 | -1,181 | 604 | 2,209 |
| Equity | 200 | 5,933 | 7,794 | 12,141 | 8,529 | 7,348 | 7,952 | 10,161 |
| Liabilities | - | - | - | - | 130,523 | 76,882 | 53,538 | 90,362 |
| Non-current assets | 0 | 0 | 1,494 | 2,008 | 23,383 | 21,046 | 16,454 | 12,133 |
| Current assets | 15,528 | 30,795 | 57,601 | 59,253 | 115,669 | 63,184 | 45,036 | 88,390 |
| Total assets | 15,528 | 30,795 | 59,095 | 61,261 | 139,052 | 84,230 | 61,490 | 100,523 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 23,543 | 20,876 | 23,601 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +67.7% | +6.8% | +76.7% | +53.1% | +43.9% | -20.2% | +26.0% | +18.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 9.5% | 19.3% | 3.1% | 7.1% | -2.6% | -1.4% | 1.0% | 2.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 741.0% | 100.0% | 23.9% | 35.8% | -42.3% | -16.1% | 7.6% | 21.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.7% | 13.7% | 2.4% | 3.7% | -2.1% | -0.9% | 0.4% | 1.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.7% | 14.5% | 2.6% | 3.9% | -2.0% | -0.9% | 0.4% | 1.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 15.3 | 10.5 | 6.7 | 8.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 40,425 | 43,185 | 76,288 | 116,787 | 168,109 | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
DNA Studija - Social security debts
The company had no debts to Sodra
DNA Studija - VMI tax arrears
As of 2026-10-07, the amount of overdue STI tax debt of the company DNA Studija is: 11 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-28 | 2026-10-07 | 10.92 |
| 2026-09-03 | 2026-09-14 | 2918.17 |
| 2026-09-01 | 2026-09-02 | 2916.61 |
| 2026-08-31 | 2026-08-31 | 2892.28 |
| 2026-08-28 | 2026-08-30 | 2887.0 |
| 2026-06-28 | 2026-07-07 | 2.0 |
| 2026-04-30 | 2026-05-12 | 0.11 |
| 2026-04-01 | 2026-04-24 | 0.11 |
| 2026-03-20 | 2026-03-27 | 8.74 |
| 2026-02-28 | 2026-03-11 | 8.74 |
| 2026-01-29 | 2026-01-29 | 1954.21 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
DNA Studija, MB (code 304292551) is a Lithuanian small partnership engaged in architectural activities. In the latest financial year, 2025, the company generated revenue of €200.7K, up 18.7% year on year and 49.6% over two years. Profitability also improved: net profit increased from a loss of €1.2K in 2023 to €604 in 2024 and €2.2K in 2025. The 2025 profit margin was 1.1%, indicating a modest but positive operating result. Balance sheet size expanded to €100.5K in 2025, compared with €61.5K in 2024 and €84.2K in 2023. Equity rose gradually to €10.2K, while liabilities increased to €90.4K. Key ratios point to a leveraged capital structure, with an equity ratio of 10.1% and debt-to-equity of 8.89x. Return on equity was 21.7% and return on assets 2.2%, supported by an asset turnover of 2.00x.